Aurobindo Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹94.2K Cr
Consolidated revenues increased by 16% YoY to Rs. Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
From Aurobindo Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹1,615
Market Cap
₹94.2K Cr
P/E Ratio
24.9
How does Aurobindo Pharma rank in Pharmaceuticals & Biotechnology?
Compare Aurobindo Pharma against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Aurobindo Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹8.9K Cr, net profit ₹921 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Consolidated revenues increased by 16% YoY to Rs. 9,150 crores, driven by broad-based business performance.
- →Formulation business grew 17% YoY, contributing ~89% of revenues.
- →U.S. revenues up 8.1% YoY with 10 new product launches and 9 ANDA filings in the quarter.
- →European business expects double-digit growth in FY27 with continued new launches.
- →Growth markets increased 38% YoY, with expansion in countries like Indonesia, China, and Canada.
- →FY27 guidance: double-digit revenue growth, EBITDA margins above 21%, EBITDA exceeding Rs. 8,000 crores.
- →Biosimilar and biological CMO businesses are long-term growth drivers.
- →TheraNym CDMO revenues expected to start from 2028 (~$150-$200 million by 2032) with 35-50% EBITDA margins.
- →China facility production doubled, aiming to exceed 2 billion tablets by mid-next year.
- →Strong pipeline execution with multiple near-term product filings, especially in complex respiratory and controlled substance portfolios.
See what Aurobindo Pharma said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
Yes- →Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
- →The Lannett acquisition has provided substantial manufacturing capacity and strategic benefits with minimal additional CAPEX needed in the short term.
- →Aurobindo has scope for expansion at existing facilities, including Lannett and Aurolife units, and has a reserve facility that can be quickly brought online if required.
- →The recent acquisition of A1 Biochem (a CRO) complements existing API capabilities, aiming to develop an integrated CRDMO, accelerating growth by 3-5 times over 3-5 years versus greenfield investment taking 5 years.
- →Focus on backward integration and investment in complex generics, specialty pharmaceuticals, injectables, biologics, and CDMO services to build durable competitive advantages and improve returns.
- →Overall, investments made over the last decade are transitioning from the investment phase to monetization, improving margins, cash flows, and returns on capital.
See what Aurobindo Pharma said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
No informationKey Metrics
1 of 5 growth signals positive in the Q1 FY27 call.
Revenue
Margin
Capex
Fundraise
Order Book
How does Aurobindo Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
Continue your research
What Aurobindo Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Ind-Swift Laboratories Ltd (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…
- HIKAL (Q1 FY27)
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…
Frequently Asked Questions
What were Aurobindo Pharma Q1 FY27 results?
Consolidated revenues increased by 16% YoY to Rs. Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
What is Aurobindo Pharma share price analysis?
Aurobindo Pharma currently shows a below-average growth signal. The stock trades at a P/E of 24.9 with a market cap of ₹94,165 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aurobindo Pharma planning capital expenditure?
Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
Keep Aurobindo Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.